BioBridgeX
Log inCompare quotes
CMC / Manufacturing

LNP / Delivery Formulation CDMOs

Free for buyersNeutral marketplace
Quick answer

LNP / Delivery formulation is the CMC work of encapsulating an mRNA, siRNA, or DNA payload inside a lipid nanoparticle so it reaches cells intact and dosable. You need it once a nucleic-acid candidate moves toward IND-enabling tox and clinical supply. On BioBridgeX, buyers source and compare qualified CDMOs for LNP formulation and encapsulation and contract directly with their chosen supplier, free for buyers.

LNP / Delivery Formulation CDMOs on BioBridgeX

We are qualifying and publishing LNP / Delivery Formulation CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is LNP / delivery formulation and when do you need it?

A lipid nanoparticle is the delivery vehicle that gets a fragile nucleic-acid payload (mRNA, siRNA, saRNA, or plasmid DNA) past the bloodstream and into the cytoplasm of a target cell. Naked RNA degrades in minutes and does not cross a cell membrane on its own, so the drug is only as good as the particle carrying it. LNP / delivery formulation is the CMC work of building that particle: combining an ionizable lipid, a helper phospholipid, cholesterol, and a PEG-lipid in the right ratio, mixing them with the payload under controlled conditions, and ending up with a uniform population of particles that encapsulate the cargo and release it where they should.

You reach this work once you have a nucleic-acid candidate worth advancing and need real, dosable material rather than a bench prep. In practice that is the run-up to IND-enabling toxicology and first clinical supply. The test article you dose in your GLP tox study has to be the same formulation, made by the same process, that goes into patients, so the formulation has to be locked and reproducible before the expensive studies start. Teams that treat LNP as an afterthought, optimizing the RNA for a year and the particle for a month, usually pay for it later in a tox study they have to repeat.

The deciding variables a buyer actually cares about are encapsulation efficiency (how much of your payload made it inside the particles versus floating free), particle size and polydispersity (a tight distribution around the target diameter, typically measured by dynamic light scattering), zeta potential, lipid and RNA identity and purity, and in vitro potency in a relevant cell line. Get those wrong and biodistribution shifts, potency drops, and immunogenicity climbs. This is a specialist process, not a generic fill, which is why most sponsors source it from a CDMO that runs microfluidic or T-mixing LNP manufacturing as a core capability rather than a side offering.

What does an LNP / delivery formulation CDMO actually do?

An LNP CDMO takes your payload and your lipid components and turns them into a characterized, scalable drug product. The front of the engagement is formulation and process development: screening or transferring a lipid composition, dialing in the mixing process (microfluidics or a confined-impingement-jet / T-mixer at small scale, moving to controlled crossflow systems as volume grows), and setting the parameters that control particle size and encapsulation. They also handle the buffer exchange and concentration steps (tangential flow filtration) that remove ethanol and free lipid and bring the particles to the final formulation.

Alongside the process sits the analytical package, and it is where a lot of programs quietly stall. The CDMO develops and qualifies the methods that release and characterize the product: RNA encapsulation efficiency (commonly a RiboGreen assay), particle size and polydispersity by dynamic light scattering, lipid content and identity by HPLC or LC-MS, RNA integrity, residual ethanol and solvent, endotoxin, sterility, and pH and osmolality. For a regulatory filing you need these methods validated, plus a stability program (often under frozen or refrigerated storage, since LNPs are temperature-sensitive) showing the particle holds together and the payload stays intact over time.

From there the work scales: tech transfer of a working process into a GMP suite, engineering and GMP batches, aseptic fill-finish into vials, and lot release against a specification. Some CDMOs cover the whole chain (lipid supply or ionizable-lipid synthesis, RNA drug substance, LNP formulation, and fill-finish under one roof); others specialize in the formulation step and coordinate with your RNA and fill suppliers. Knowing which model a supplier runs, and whether they can carry you from a non-GMP feasibility batch through to GMP clinical supply without a second tech transfer, is one of the first things to pin down.

How to choose an LNP / delivery formulation CDMO?

Match the supplier to where your program actually is and where it is going. A shop that makes beautiful research-grade particles in a glovebox is not the same as one with GMP suites, a validated analytical package, and a clean regulatory inspection record, and paying for the second when you need the first wastes money the other direction too. The questions below are the ones that separate a partner who gets you to clinic on schedule from one who hands you a tech transfer to redo.

  • Quality and GxP status: confirm whether the work you need is non-GMP feasibility or GMP clinical supply, ask for the quality system, recent FDA or EMA inspection history, and whether their LNP analytical methods (encapsulation, particle size, lipid content, RNA integrity) are qualified or fully validated.
  • Capacity and lead time: LNP GMP slots and specialty fill capacity book out months ahead, so ask for the realistic queue, batch sizes available now versus at scale, and the lead time on ionizable lipid and other raw materials, which is often the real critical path.
  • Modality and indication fit: a CDMO strong in mRNA vaccine LNPs may be unproven on siRNA, self-amplifying RNA, or a targeted / non-liver delivery program, so ask for completed work in your specific payload and route, not just a generic LNP claim.
  • Region and regulatory track record: confirm the site supports the agencies you plan to file with (FDA, EMA, PMDA), how many of their LNP programs have cleared an IND or equivalent, and whether they can author the CMC sections you will need.
  • Data quality and transfer: ask exactly which release and characterization data you receive, how a working process and methods transfer to you or a downstream site, and whether their feasibility data will actually support the GMP campaign or has to be regenerated.
  • IP and confidentiality: settle who owns process improvements and formulation know-how developed on your dollar, whether they use a proprietary lipid you would be locked into, and how they protect a sequence or composition you have not disclosed.

Frequently asked questions

What is the difference between LNP formulation and fill-finish?
LNP formulation is the step that builds the particle: mixing the ionizable lipid, helper lipid, cholesterol, and PEG-lipid with your nucleic-acid payload under controlled conditions, then removing solvent and concentrating to the final formulation. Fill-finish is the later sterile step that fills that finished drug product into vials or syringes, often with lyophilization, under aseptic GMP control. Some CDMOs do both under one roof; many do not, so confirm whether you are buying formulation only, fill only, or an integrated process. Both must be GMP for material that goes into patients.
When in development do I need to lock my LNP formulation?
Before IND-enabling toxicology and first clinical supply, not after. The test article dosed in your GLP tox studies has to match the formulation, made by the same process, that goes into patients, so the lipid composition, the encapsulation process, and the analytical methods need to be fixed before those studies start. Changing the formulation afterward can mean repeating tox work, which is the multi-month, high-cost delay sponsors are trying to avoid. Early feasibility and lipid screening can run non-GMP, but the locked process should be GMP-ready by the time you commit to the pivotal program.
How is LNP encapsulation efficiency measured and why does it matter?
Encapsulation efficiency is the fraction of your payload that ended up inside the lipid nanoparticles rather than free in solution, and it is most often measured with a RiboGreen fluorescence assay run with and without a detergent that breaks the particles open. It matters because free, unencapsulated RNA is degraded fast and does not reach the target cell, so low encapsulation means you are dosing less active drug than the label says and the dose-response gets muddy. It is one of the core release specifications, alongside particle size, polydispersity, lipid content, and RNA integrity.
Does my LNP formulation work need to be done under GMP?
It depends on the batch. CMC manufacturing of drug product for a patient runs under Good Manufacturing Practice (GMP), so any LNP material going into a clinical trial, and the matching test article for your GLP tox studies, should be made under GMP with validated release methods. Early formulation screening, lipid composition work, and feasibility batches can run non-GMP to fail cheaply and lock the process before you pay GMP prices. The trap is assuming non-GMP feasibility data will support the GMP campaign without rework, so confirm with the CDMO which batches are which before you sign.
Can the same CDMO make my RNA drug substance and the LNP drug product?
Sometimes, and it can save a tech transfer, but do not assume it. Some CDMOs cover the full nucleic-acid chain (ionizable lipid synthesis or supply, mRNA or plasmid drug substance, LNP formulation, and fill-finish), while others specialize only in the formulation step and coordinate with your separate RNA and fill suppliers. An integrated supplier reduces handoffs and timeline risk; a best-of-breed split can give you a stronger specialist at each step. On BioBridgeX you can compare both models and, when you do split the work across suppliers, still contract directly with each chosen supplier in one place.
How does sourcing an LNP / delivery formulation CDMO through BioBridgeX work?
You describe the work (your payload type, route, batch scale, GMP or feasibility, and timeline) and get matched with qualified CDMOs that run LNP formulation as a core capability, then compare them on capacity, modality fit, analytical and quality status, and transparent quotes in one view. BioBridgeX is a neutral marketplace that runs no labs of its own, so there is no incentive to steer you toward a house supplier. It is free for buyers; suppliers pay a flat 2% platform fee. When a program needs more than one supplier, you still compare quotes and contract directly with each chosen supplier in one place.

Source LNP / Delivery Formulation with one contract

Compare transparent quotes from qualified LNP / Delivery Formulation CDMOs, then contract once. Free for buyers.

Compare quotes